Nasdaq

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®

- Monotherapy arm has advanced to a fourth cohort, with initial monotherapy PK and safety data expected in the fourth quarter of 2023 and topline monotherapy data expected in 2024 - - New guidance for ...
Nasdaq

Sensei Biotherapeutics Announces Anticipated Full Enrollment of Solnerstotug (SNS-101) Dose Expansion Arm by End of Q1 2025 and Upcoming Clinical Data Update

Sensei Biotherapeutics, Inc. announced key updates regarding its lead program, solnerstotug (SNS-101), a treatment targeting the immune checkpoint VISTA in advanced solid tumors. The company ...
Kotaku

The Ramen Sensei 2

All the Latest Game Footage and Images from The Ramen Sensei 2 Noodles, soup - easy! Think again! Get your apron on, it's time to learn about the complexities and wonders that is ramen. Have what it ...